Date: 2015-04-13
Type of information: Milestone
Compound: guselkumab (CNTO1959)
Company: MorphoSys (Germany) Janssen Biotech, a J&J company (USA - NJ)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: R&D - research
Action mechanism: monoclonal antibody. Guselkumab is a human monoclonal antibody that targets interleukin (IL)-23, and is in Phase 3 clinical development as a subcutaneously administered therapy for the treatment of moderate to severe plaque psoriasis.
Disease: psoriatic arthritis
Details:
- • On April 13, 2015, MorphoSys announced that Janssen Biotech has initiated a phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
- MorphoSys's collaboration with Janssen has resulted in three clinical programs to date, two of which are in phase 2 development and one, guselkumab, in phase 3 in psoriasis (most advanced trial). In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 23 unique antibody molecules which are being evaluated in more than 60 clinical trials.
Financial terms:
Latest news:
Is general: Yes